United States

Galenica AG (GALN.S)

GALN.S on Virt-X Level 1

25 Oct 2016
Change (% chg)

CHF-11.00 (-1.10%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for GALN.S


Galenica AG is a Switzerland-based company engaged in the healthcare market. The Company, among other activities, develops, manufactures and markets pharmaceutical products; provides logistical services; runs pharmacies; offers database services, and sets up networks through its four divisions: Pharma, mainly active in the iron... (more)


Beta: 0.59
Market Cap(Mil.): CHF6,470.75
Shares Outstanding(Mil.): 6.50
Dividend: 18.00
Yield (%): 1.81


  GALN.S Industry Sector
P/E (TTM): 19.64 20.73 43.30
EPS (TTM): 50.70 -- --
ROI: 15.24 12.04 67.66
ROE: 18.69 13.83 78.28

BRIEF-Galenica appoints new CFO, new management at Vifor Pharma

* New management at Vifor Pharma and new Galenica Group CFO designated

Oct 06 2016

BRIEF-Galenica H1 net profit after minorities up 21.5 pct at 158.9 mln Swiss francs

* H1 net profit before deduction of minority interests rose by 23.3 pct to 194.6 million Swiss francs ($197.99 million) and net profit after deduction of minority interests rose by 21.5 pct to 158.9 million Swiss francs

Aug 09 2016

BRIEF-Galenica: Vifor Pharma USA initiates tender offer for Relypsa

* Galenica Group today announced that its indirect wholly owned subsidiary, Vifor Pharma USA Inc initiates tender offer for Relypsa Source text - http://bit.ly/2avY0sG Further company coverage: (Gdynia Newsroom)

Aug 04 2016

Deals of the day- Mergers and acquisitions

July 21 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

Jul 21 2016

BRIEF-Relypsa to pay $49 mln to Galenica AG if deal called off

* Co to pay Galenica AG termination fee of $49 million in cash if deal is terminated Source text for Eikon: Further company coverage:

Jul 21 2016

Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split

Galenica has agreed to buy Relypsa for $1.53 billion, paying a big premium for the Californian biotech company to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group.

Jul 21 2016

UPDATE 2-Galenica to buy biotech firm Relypsa for $1.5 bln, ahead of split

* Galenica shares down 7 percent (Adds analyst reaction, latest shares, advisers)

Jul 21 2016

Galenica to acquire U.S. biopharma firm Relypsa for $1.53 bln in cash

July 21 Galenica said it has agreed to buy U.S. biopharma company Relypsa for $1.53 billion in cash to strengthen its Vifor Pharma unit.

Jul 21 2016

BRIEF-Galenica to buy Relypsa to strengthen its unit Vifor Pharma

* Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion

Jul 21 2016

BRIEF-Galenica decides to appoint new CEO for Vifor Pharma

* Vifor Pharma to further strengthen company management to ensure continued strong growth

May 24 2016

Earnings vs. Estimates